The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Effects of Tiotropium With and Without Formoterol on Airflow Obstruction and Resting Hyperinflation in Patients With COPD
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“After the 2-week treatment periods, they confirmed additive effects on lung deflation with significant increases in average daily IC and daytime peak IC with the combination treatment versus tiotropium alone.”
From Lung hyperinflation in COPD: applying physiology to clinical practice (2015) · cites this paper as [86]
In the citing paper
“The combination of a long-acting muscarinic antagonist (LAMA) and a long-acting β 2 -agonist (LABA) can have additive effects on reducing lung hyperinflation [86,87].”
From Lung hyperinflation in COPD: applying physiology to clinical practice (2015) · cites this paper as [86]
In the citing paper
“Importantly, the mechanical benefits were also evident throughout the night.”
From Lung hyperinflation in COPD: applying physiology to clinical practice (2015) · cites this paper as [86]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
O'DONNELL, D. E., LAM, M., & WEBB, K. A. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.158.5.9804004 · Cited by 532
Research works printed but not linked: 27
- Celik, 1999, Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: a crossover, placebo-controlled comparison of onset and duration of action, Respiration, 66, 434, 10.1159/000029427 · DOI
- Tashkin, 2004, The role of long-acting bronchodilators in the management of stable COPD, Chest, 125, 249, 10.1378/chest.125.1.249 · DOI
- Casaburi, 2002, A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease, Eur Respir J, 19, 217, 10.1183/09031936.02.00269802 · DOI
- Vincken, 2002, Improved health outcomes in patients with COPD during 1 yr’s treatment with tiotropium, Eur Respir J, 19, 209, 10.1183/09031936.02.00238702 · DOI
- O’Donnell, 2004, Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD, Eur Respir J, 23, 832, 10.1183/09031936.04.00116004 · DOI · Paper page
- 1994, Combivent Inhalation Aerosol Study Group.. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone, Chest, 105, 1411, 10.1378/chest.105.5.1411 · DOI
- 1997, Combivent Inhalation Solution Study Group.. Routine nebulized ipratropium and albuterol together are better than either alone in COPD, Chest, 112, 1514, 10.1378/chest.112.6.1514 · DOI
- Campbell, 1999, For COPD, a combination of ipratropium bromide and albuterol sulphate is more effective than albuterol base, Arch Intern Med, 159, 156, 10.1001/archinte.159.2.156 · DOI
- Cazzola, 2004, The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD, Pulm Pharm Ther, 17, 35, 10.1016/j.pupt.2003.09.001 · DOI
- Van Noord, 2005, Comparison of tiotropium qd, formoterol bid and both combined qd in patients with COPD, Eur Respir J, 26, 214, 10.1183/09031936.05.00140404 · DOI
- 1995, American Thoracic Society.. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 152, S77
- Quanjer, 1993, Lung volumes and forced ventilatory flows: Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal, Eur Respir J, 6(suppl 16), 5, 10.1183/09041950.005s1693 · DOI
- Van Noord, 2003, Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease, Eur Respir J, 19, 639, 10.1183/09031936.02.00238002 · DOI
- 1991, American Thoracic Society.. Lung function testing: selection of reference values and interpretative strategies, Am Rev Respir Dis, 144, 1202, 10.1164/ajrccm/144.5.1202 · DOI
- Calverley, 2003, Bronchodilator reversibility testing in chronic obstructive pulmonary disease, Thorax, 58, 659, 10.1136/thorax.58.8.659 · DOI
- Postma, 1985, Influence of the parasympathetic and sympathetic nervous system on nocturnal bronchial obstruction, Clin Sci, 69, 251, 10.1042/cs0690251 · DOI
- Calverley, 2003, Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease, Thorax, 58, 855, 10.1136/thorax.58.10.855 · DOI
- Di Marco, 2003, Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD, Eur Respir J, 21, 86, 10.1183/09031936.03.00020102 · DOI
- Celli, 2003, Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased lung volumes, Chest, 124, 1743, 10.1378/chest.124.5.1743 · DOI
- Ulrik, 1995, Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomized, double-blind, placebo-controlled, crossover study, Thorax, 50, 750, 10.1136/thx.50.7.750 · DOI
- Donohue, 2000, Circadian patters of rescue β2-agonist use in COPD [abstract], Eur Respir J, 16 (suppl 31), 56s
- Van Noord, 2000, Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium, Eur Respir J, 15, 878, 10.1034/j.1399-3003.2000.15e11.x · DOI
- Chapman, 2002, The addition of salmeterol 50 μg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial, Can Respir J, 9, 178, 10.1155/2002/493296 · DOI
- Sichletidis, 1999, Bronchodilatory responses to formoterol, ipratropium, and their combination in patients with stable COPD, Int J Clin Pract, 53, 185, 10.1111/j.1742-1241.1999.tb11699.x · DOI
- D’Urzo, 2001, In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium: a 3-week, randomized, double-blind, within-patient multicenter study, Chest, 119, 1347, 10.1378/chest.119.5.1347 · DOI
- Yates, 1995, Regular formoterol treatment in mild asthmatics: effect on bronchial responsiveness during and after treatment, Am J Respir Crit Care Med, 152, 1170, 10.1164/ajrccm.152.4.7551366 · DOI
- Tennant, 2003, Long-acting β2-adrenoceptor agonists or tiotropium bromide for patients with COPD: is combination therapy justified?, Curr Opin Pharmacol, 3, 270, 10.1016/S1471-4892(03)00047-X · DOI
Cited by
The major limitation to exercise performance in COPD is dynamic hyperinflation
O'Donnell, D. E., & Webb, K. A. (2008) · Journal of Applied Physiology · doi:10.1152/japplphysiol.90336.2008b · Cited by 221
Inspiratory Capacity during Exercise: Measurement, Analysis, and Interpretation
Guenette, J. A., Chin, R. C., Cory, J. M., Webb, K. A., & O'Donnell, D. E. (2013) · Pulmonary Medicine · doi:10.1155/2013/956081 · Cited by 203
Lung hyperinflation in COPD: applying physiology to clinical practice
O’Donnell, D. E., Webb, K. A., & Neder, J. A. (2015) · COPD Research and Practice · doi:10.1186/s40749-015-0008-8 · Cited by 93
Effects of inspiratory muscle training on dynamic hyperinflation in patients with COPD
Petrovic, M., Reiter, Wanke, Pohl, & Zipko (2012) · International Journal of Chronic Obstructive Pulmonary Disease · doi:10.2147/copd.s23784 · Cited by 83
Metadata
- Authors
- van Noord, J. A., Aumann, J. L., Janssens, E., Verhaert, J., Smeets, J. J., Mueller, A., & Cornelissen, P. J. G.
- Venue
- Chest
- Publisher
- Elsevier BV
- Published
- 2006-03
- Volume
- 129
- Issue
- 3
- Pages
- 509-517
- ISSN
- 0012-3692
- Cited by
- 203
- References
- 1
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
